SCIENTIFIC REPORT 2015

Staining for a
cytoskeleton
regulating protein
kinases in kidney by
Immunohistochemistry.
Expression (brown) is
specifically localised to
the glomeruli.
Image supplied by
Claus Jorgensen
(Systems Oncology)
and Garry Ashton
(Histology)
Alison McGonagle, Allan Jordan, Bohdan
Waszkowycz, Colin Hutton, Ian Waddell, James
Hitchin, Kate Smith, Niall Hamilton.
“Inhibitory Compounds” PCT/GB2015/054064,
Filing date 17th December, 2015.
Tim Somervaille (page 26)
Leukaemia Biology
Korfi K, Mandal A, Furney SJ, Wiseman D,
Somervaille TC, Marais R. (2015)
A personalised medicine approach for ponatinibresistant
chronic myeloid leukaemia. Ann Oncol.,
26(6):1180-7.
Other publications
Williams MS, Somervaille TC. (2015)
Leukemogenic Activity of Cohesin Rings True.
Cell Stem Cell, 17(6):642-4.
Zelenay S, van der Veen AG, Böttcher JP, Snelgrove
KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR,
Marais R, Quezada SA, Sahai E, Reis e Sousa C.
(2015)
Cyclooxygenase-Dependent Tumor Growth
through Evasion of Immunity. Cell, 162(6):1257-70.
Conde-Perez A, Gros G, Longvert C, Pedersen M,
Petit V, Aktary Z, Viros A, Gesbert F, Delmas V,
Rambow F, Bastian BC, Campbell AD, Colombo S,
Puig I, Bellacosa A, Sansom O, Marais R, Van
Kempen LC, Larue L. (2015)
A caveolin-dependent and PI3K/AKT-independent
role of PTEN in β-catenin transcriptional activity.
Nat Commun., 6:8093.
Miller BW, Morton JP, Pinese M, Saturno G,
Jamieson NB, McGhee E, Timpson P, Leach J,
McGarry L, Shanks E, Bailey P, Chang D, Oien K,
Karim S, Au A, Steele C, Carter CR, McKay C,
Anderson K, Evans TR, Marais R, Springer C, Biankin
A, Erler JT, Sansom OJ. (2015)
Targeting the LOX/hypoxia axis reverses many of
the features that make pancreatic cancer deadly:
inhibition of LOX abrogates metastasis and
enhances drug efficacy. EMBO Mol Med.,
7(8):1063-76.
Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ,
Martínez-Cardús A, Girotti MR, Villanueva A, Guil S,
Moutinho C, Liz J, Portela A, Heyn H, Moran S,
Vidal A, Martinez-Iniesta M, Manzano JL,
Fernandez-Figueras MT, Elez E, Muñoz-Couselo E,
Botella-Estrada R, Berrocal A, Pontén F, Oord Jv,
Gallagher WM, Frederick DT, Flaherty KT,
McDermott U, Lorigan P, Marais R, Esteller M.
(2015)
Epigenetic activation of a cryptic TBC1D16
transcript enhances melanoma progression by
targeting EGFR. Nat Med., 21(7):741-50.
Combination With Oncolytic Reovirus Through ER
Stress. Mol Ther., 23(5):931-42.
Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D,
Zambon A, Davies L, Whittaker S, Saturno G, Viros
A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary
R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B,
Hohloch J, Carragher N, Macleod K, Ashton G,
Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan
P, Marais R, Springer C. (2015)
Paradox-breaking RAF inhibitors that also target
SRC are effective in drug-resistant BRAF mutant
melanoma. Cancer Cell, 27(1):85-96.
Other publications
Marais R. (2015)
RETROSPECTIVE. Christopher Marshall (1949-
2015). Science, 350(6264):1040.
Crispin Miller (page 32)
RNA Biology
Refereed Research Papers
Thambyrajah R, Mazan M, Patel R, Moignard V,
Stefanska M, Marinopoulou E, Li Y, Lancrin C,
Clapes T, Möröy T, Robin C, Miller C, Cowley S,
Göttgens B, Kouskoff V, Lacaud G. (2015)
GFI1 proteins orchestrate the emergence of
haematopoietic stem cells through recruitment of
LSD1. Nat Cell Biol., Epub 2015 Nov 30.
Refereed Research Papers
Somerville TD, Wiseman DH, Spencer GJ, Huang
X, Lynch JT, Leong HS, Williams EL, Cheesman E,
Somervaille TC. (2015)
Frequent Derepression of the Mesenchymal
Transcription Factor Gene FOXC1 in Acute Myeloid
Leukemia. Cancer Cell, 28(3):329-42.
Maes T, Mascaró C, Ortega A, Lunardi S, Ciceri F,
Somervaille TC, Buesa C. (2015)
KDM1 histone lysine demethylases as targets for
treatments of oncological and neurodegenerative
disease. Epigenomics, 7(4):609-26.
Wiseman DH, Struys EA, Wilks DP, Clark CI,
Dennis MW, Jansen EE, Salomons GS, Somervaille
TC. (2015)
Direct comparison of quantitative digital PCR and
2-hydroxyglutarate enantiomeric ratio for IDH
mutant allele frequency assessment in myeloid
malignancy. Leukemia, 29(12):2421-3.
Richard Marais (page 28)
Molecular Oncology
Refereed Research Papers
Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D,
Viros A, Mandal AK, Lim KH, Saturno G, Furney SJ,
Baenke F, Pedersen M, Rogan J, Swan J, Smith M,
Fusi A, Oudit D, Dhomen N, Brady G, Lorigan P,
Dive C, Marais R. (2015)
Application of sequencing, liquid biopsies and
patient-derived xenografts for personalized
medicine in melanoma. Cancer Discovery, pii:
CD-15-1336. Epub 29 December 2015.
Baenke F, Chaneton B, Smith M, Van Den Broek N,
Hogan K, Tang H, Viros A, Martin M, Galbraith L,
Girotti MR, Dhomen N, Gottlieb E, Marais R. (2015)
Resistance to BRAF inhibitors induces glutamine
dependency in melanoma cells.
Molecular Oncology, Epub 2015 Aug 20.
Hirata E, Girotti MR, Viros A, Hooper S, Spencer-
Dene B, Matsuda M, Larkin J, Marais R, Sahai E.
(2015)
Intravital imaging reveals how BRAF inhibition
generates drug-tolerant microenvironments with
high integrin β1/FAK signaling. Cancer Cell,
27(4):574-88.
Korfi K, Mandal A, Furney SJ, Wiseman D,
Somervaille TC, Marais R. (2015)
A personalised medicine approach for ponatinibresistant
chronic myeloid leukaemia. Ann Oncol.,
26(6):1180-7.
Roulstone V, Pedersen M, Kyula J, Mansfield D,
Khan AA, McEntee G, Wilkinson M, Karapanagiotou
E, Coffey M, Marais R, Jebar A, Errington-Mais F,
Melcher A, Vile R, Pandha H, McLaughlin M,
Harrington KJ. (2015)
BRAF- and MEK-Targeted Small Molecule Inhibitors
Exert Enhanced Antimelanoma Effects in
56 SCIENTIFIC REPORT 2015 CANCER RESEARCH UK MANCHESTER INSTITUTE RESEARCH PUBLICATIONS
57